

Tracy L Greer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10497028/publications.pdf>

Version: 2024-02-01

69
papers

2,484
citations

236925

25
h-index

206112

48
g-index

70
all docs

70
docs citations

70
times ranked

3254
citing authors

#	ARTICLE	IF	CITATIONS
1	A primary care first (PCP-first) model to screen and treat depression: A VitalSign6 report from a second cohort of 32,106 patients. <i>General Hospital Psychiatry</i> , 2022, 74, 1-8.	2.4	5
2	Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2022, 149, 243-251.	3.1	4
3	Dorsolateral Prefrontal Cortex and Subcallosal Cingulate Connectivity Show Preferential Antidepressant Response in Major Depressive Disorder. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 20-28.	1.5	6
4	Moderators of treatment response to exercise in participants with stimulant use disorder: Exploratory results from the Stimulant Reduction using Dosed Exercise (STRIDE)CTN-0037 study. <i>Mental Health and Physical Activity</i> , 2021, 21, 100421.	1.8	0
5	Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression. <i>American Journal of Psychiatry</i> , 2020, 177, 143-154.	7.2	76
6	Dysfunctional adaptive immune response in adolescents and young adults with suicide behavior. <i>Psychoneuroendocrinology</i> , 2020, 111, 104487.	2.7	26
7	Comprehensive phenotyping of depression disease trajectory and risk: Rationale and design of Texas Resilience Against Depression study (T-RAD). <i>Journal of Psychiatric Research</i> , 2020, 122, 22-32.	3.1	21
8	Pharmacological and Nonpharmacological Treatment Effects on Functional Outcomes in Major Depressive Disorder. , 2020, , 131-146.		2
9	Identifying and responding to trial implementation challenges during multisite clinical trials. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 63-72.	2.8	5
10	The Promise of Biomarkers for Psychiatry. <i>Psychiatric Annals</i> , 2020, 50, 236-237.	0.1	0
11	A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project. <i>Annals of Family Medicine</i> , 2019, 17, 326-335.	1.9	32
12	The Stimulant Selective Severity Assessment: A replication and exploratory extension of the Cocaine Selective Severity Assessment. <i>Substance Use and Misuse</i> , 2019, 54, 351-361.	1.4	3
13	VitalSign6: A Primary Care First (PCP-First) Model for Universal Screening and Measurement-Based Care for Depression. <i>Pharmaceuticals</i> , 2019, 12, 71.	3.8	33
14	Acute and long-term cannabis use among stimulant users: Results from CTN-0037 Stimulant Reduction Intervention using Dosed Exercise (STRIDE) Randomized Control Trial. <i>Drug and Alcohol Dependence</i> , 2019, 200, 139-144.	3.2	3
15	Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study. <i>Journal of Psychiatric Research</i> , 2019, 113, 165-171.	3.1	33
16	Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial. <i>Journal of Affective Disorders</i> , 2018, 234, 34-37.	4.1	50
17	A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder. <i>Journal of Psychiatric Research</i> , 2018, 102, 65-71.	3.1	14
18	A complier average causal effect analysis of the Stimulant Reduction Intervention using dosed exercise study. <i>Contemporary Clinical Trials Communications</i> , 2018, 10, 1-8.	1.1	9

#	ARTICLE	IF	CITATIONS
19	Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study. <i>Journal of Psychiatric Research</i> , 2018, 102, 207-215.	3.1	12
20	Stability, reliability, and validity of the THINC-it screening tool for cognitive impairment in depression: A psychometric exploration in healthy volunteers. <i>International Journal of Methods in Psychiatric Research</i> , 2018, 27, e1736.	2.1	27
21	Psychometrics of the Self-Report Concise Associated Symptoms Tracking Scale (CAST-SR). <i>Journal of Clinical Psychiatry</i> , 2018, 79, 41-47.	2.2	5
22	Evaluation of the benefits of exercise on cognition in major depressive disorder. <i>General Hospital Psychiatry</i> , 2017, 49, 19-25.	2.4	17
23	Prediction of treatment outcomes to exercise in patients with nonremitted major depressive disorder. <i>Depression and Anxiety</i> , 2017, 34, 1116-1122.	4.1	28
24	Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection. <i>Brain, Behavior, and Immunity</i> , 2017, 66, 103-110.	4.1	60
25	Psychosocial relationship status and quality as predictors of exercise intervention adherence and substance use outcomes: Results from the STRIDE (CTN-0037) study. <i>Psychiatry Research</i> , 2017, 254, 332-339.	3.3	2
26	Cardiorespiratory fitness and body composition of stimulant users: A baseline analysis of the STRIDE cohort. <i>Journal of Substance Abuse Treatment</i> , 2017, 78, 74-79.	2.8	5
27	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017, 222, 14-20.	4.1	39
28	An ounce of prevention: A pre-randomization protocol to improve retention in substance use disorder clinical trials. <i>Addictive Behaviors</i> , 2017, 64, 137-142.	3.0	7
29	Editorial: Eyeblink Classical Conditioning in Psychiatric Conditions: Novel Uses for a Classic Paradigm. <i>Frontiers in Psychiatry</i> , 2017, 8, 48.	2.6	2
30	Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 803-813.	2.2	21
31	Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1075-1082.	2.2	53
32	The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 873-881.	2.2	100
33	Affect Following First Exercise Session as a Predictor of Treatment Response in Depression. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1036-1042.	2.2	15
34	The Treatment with Exercise Augmentation for Depression (TREAD) study. , 2016, , 96-108.		1
35	IMPROVEMENTS IN PSYCHOSOCIAL FUNCTIONING AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING EXERCISE AUGMENTATION IN PATIENTS WITH TREATMENT RESPONSE BUT NONREMITTED MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE TREAD STUDY. <i>Depression and Anxiety</i> , 2016, 33, 870-881.	4.1	31
36	Atypical depressive symptoms as a predictor of treatment response to exercise in Major Depressive Disorder. <i>Journal of Affective Disorders</i> , 2016, 200, 156-158.	4.1	15

#	ARTICLE	IF	CITATIONS
37	Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. <i>American Journal of Psychiatry</i> , 2016, 173, 1196-1204.	7.2	40
38	Early normalization of Quality of Life predicts later remission in depression: Findings from the CO-MED trial. <i>Journal of Affective Disorders</i> , 2016, 206, 17-22.	4.1	26
39	Baseline medical comorbidities in adults randomized in the STRIDE trial for psychostimulant use disorders. <i>American Journal on Addictions</i> , 2016, 25, 215-220.	1.4	4
40	Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients. <i>PLoS ONE</i> , 2016, 11, e0167901.	2.5	26
41	Evaluation of anhedonia with the Snaithâ€“Hamilton Pleasure Scale (SHAPS) in adult outpatients with major depressive disorder. <i>Journal of Psychiatric Research</i> , 2015, 65, 124-130.	3.1	36
42	Dose-dependent changes in cognitive function with exercise augmentation for major depression: Results from the TREAD study. <i>European Neuropsychopharmacology</i> , 2015, 25, 248-256.	0.7	53
43	Comorbidities and Race/Ethnicity Among Adults with Stimulant Use Disorders in Residential Treatment. <i>Journal of Ethnicity in Substance Abuse</i> , 2015, 14, 79-95.	0.9	11
44	On the invariance of the Stimulant Craving Questionnaire (STCQ) across cocaine and methamphetamine users. <i>Addictive Behaviors</i> , 2015, 42, 144-147.	3.0	6
45	Men and women from the STRIDE clinical trial: An assessment of stimulant abstinence symptom severity at residential treatment entry. <i>American Journal on Addictions</i> , 2015, 24, 336-340.	1.4	7
46	Research staff training in a multisite randomized clinical trial: Methods and recommendations from the stimulant reduction intervention using dosed exercise (STRIDE) trial. <i>Addiction Research and Theory</i> , 2014, 22, 407-415.	1.9	14
47	Does Duloxetine Improve Cognitive Function Independently of Its Antidepressant Effect in Patients with Major Depressive Disorder and Subjective Reports of Cognitive Dysfunction?. <i>Depression Research and Treatment</i> , 2014, 2014, 1-13.	1.3	43
48	Cognitive dysfunction in unipolar depression: Implications for treatment. <i>Journal of Affective Disorders</i> , 2014, 152-154, 19-27.	4.1	221
49	Self-rated measure of pain frequency, intensity, and burden: Psychometric properties of a new instrument for the assessment of pain. <i>Journal of Psychiatric Research</i> , 2014, 59, 155-160.	3.1	18
50	A health education intervention as the control condition in the CTN-0037 STRIDE multi-site exercise trial: Rationale and description. <i>Mental Health and Physical Activity</i> , 2014, 7, 37-41.	1.8	11
51	Rationale and methods for site selection for a trial using a novel intervention to treat stimulant abuse. <i>Contemporary Clinical Trials</i> , 2012, 33, 29-37.	1.8	17
52	STimulant Reduction Intervention using Dosed Exercise (STRIDE) â€“ Description of the exercise intervention and behavioral program to ensure adherence. <i>Mental Health and Physical Activity</i> , 2012, 5, 175-182.	1.8	13
53	Rationale for Using Exercise in the Treatment of Stimulant Use Disorders. <i>Journal of Global Drug Policy and Practice</i> , 2012, 6, .	0.0	8
54	Determining the Primary Endpoint for a Stimulant Abuse Trial: Lessons Learned from STRIDE (CTN 0037). <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 339-349.	2.1	13

#	ARTICLE	IF	CITATIONS
55	Effects of serum Brain Derived Neurotrophic Factor on exercise augmentation treatment of depression. <i>Journal of Psychiatric Research</i> , 2011, 45, 1301-1306.	3.1	68
56	Stimulant Reduction Intervention using Dosed Exercise (STRIDE) - CTN 0037: Study protocol for a randomized controlled trial. <i>Trials</i> , 2011, 12, 206.	1.6	41
57	Exercise as an Augmentation Treatment for Nonremitted Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 677-684.	2.2	177
58	Association between depression severity and neurocognitive function in major depressive disorder: A review and synthesis. <i>Neuropsychology</i> , 2010, 24, 9-34.	1.3	292
59	Defining and Measuring Functional Recovery from Depression. <i>CNS Drugs</i> , 2010, 24, 267-284.	5.9	163
60	Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 975-984.	2.8	65
61	Exercise in the treatment of depression. <i>Current Psychiatry Reports</i> , 2009, 11, 466-472.	4.5	53
62	DATE: Depressed adolescents treated with exercise: Study rationale and design for a pilot study. <i>Mental Health and Physical Activity</i> , 2009, 2, 76-85.	1.8	19
63	The Promise of Exercise Interventions for the Anxiety Disorders. , 2008, , 81-104.		3
64	Exercise for Mood and Anxiety Disorders. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2007, 09, 287-294.	0.6	32
65	Exercise as an Augmentation Strategy for Treatment of Major Depression. <i>Journal of Psychiatric Practice</i> , 2006, 12, 205-213.	0.7	145
66	TREAD: Treatment with Exercise Augmentation for Depression: study rationale and design. <i>Clinical Trials</i> , 2006, 3, 291-305.	1.6	66
67	Impaired delay and trace eyeblink conditioning performance in major depressive disorder. <i>Journal of Affective Disorders</i> , 2005, 86, 235-245.	4.1	22
68	Remission and recovery in depression treatment. <i>Drug Development Research</i> , 2005, 65, 335-343.	2.9	8
69	Implications of cognitive impairments on functional outcomes in major depressive disorder. , 0, , 125-144.		1